- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Targeting autophagy in prostate cancer: preclinical...
Open Collections
UBC Faculty Research and Publications
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response Ashrafizadeh, Milad; Paskeh, Mahshid D. A.; Mirzaei, Sepideh; Gholami, Mohammad H.; Zarrabi, Ali; Hashemi, Farid; Hushmandi, Kiavash; Hashemi, Mehrdad; Nabavi, Noushin; Crea, Francesco; Ren, Jun; Klionsky, Daniel J.; Kumar, Alan P.; Wang, Yuzhuo, Ph.D.
Abstract
Prostate cancer is a leading cause of death worldwide and new estimates revealed prostate cancer as the leading cause of death in men in 2021. Therefore, new strategies are pertinent in the treatment of this malignant disease. Macroautophagy/autophagy is a “self-degradation” mechanism capable of facilitating the turnover of long-lived and toxic macromolecules and organelles. Recently, attention has been drawn towards the role of autophagy in cancer and how its modulation provides effective cancer therapy. In the present review, we provide a mechanistic discussion of autophagy in prostate cancer. Autophagy can promote/inhibit proliferation and survival of prostate cancer cells. Besides, metastasis of prostate cancer cells is affected (via induction and inhibition) by autophagy. Autophagy can affect the response of prostate cancer cells to therapy such as chemotherapy and radiotherapy, given the close association between autophagy and apoptosis. Increasing evidence has demonstrated that upstream mediators such as AMPK, non-coding RNAs, KLF5, MTOR and others regulate autophagy in prostate cancer. Anti-tumor compounds, for instance phytochemicals, dually inhibit or induce autophagy in prostate cancer therapy. For improving prostate cancer therapy, nanotherapeutics such as chitosan nanoparticles have been developed. With respect to the contextdependent role of autophagy in prostate cancer, genetic tools such as siRNA and CRISPR-Cas9 can be utilized for targeting autophagic genes. Finally, these findings can be translated into preclinical and clinical studies to improve survival and prognosis of prostate cancer patients. Highlights • Prostate cancer is among the leading causes of death in men where targeting autophagy is of importance in treatment;
Item Metadata
Title |
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
|
Creator | |
Publisher |
BioMed Central
|
Date Issued |
2022-03-22
|
Description |
Prostate cancer is a leading cause of death worldwide and new estimates revealed prostate cancer as the leading
cause of death in men in 2021. Therefore, new strategies are pertinent in the treatment of this malignant disease.
Macroautophagy/autophagy is a “self-degradation” mechanism capable of facilitating the turnover of long-lived and
toxic macromolecules and organelles. Recently, attention has been drawn towards the role of autophagy in cancer
and how its modulation provides effective cancer therapy. In the present review, we provide a mechanistic discussion
of autophagy in prostate cancer. Autophagy can promote/inhibit proliferation and survival of prostate cancer
cells. Besides, metastasis of prostate cancer cells is affected (via induction and inhibition) by autophagy. Autophagy
can affect the response of prostate cancer cells to therapy such as chemotherapy and radiotherapy, given the close
association between autophagy and apoptosis. Increasing evidence has demonstrated that upstream mediators such
as AMPK, non-coding RNAs, KLF5, MTOR and others regulate autophagy in prostate cancer. Anti-tumor compounds,
for instance phytochemicals, dually inhibit or induce autophagy in prostate cancer therapy. For improving prostate
cancer therapy, nanotherapeutics such as chitosan nanoparticles have been developed. With respect to the contextdependent
role of autophagy in prostate cancer, genetic tools such as siRNA and CRISPR-Cas9 can be utilized for
targeting autophagic genes. Finally, these findings can be translated into preclinical and clinical studies to improve
survival and prognosis of prostate cancer patients.
Highlights
• Prostate cancer is among the leading causes of death in men where targeting autophagy is of importance in
treatment;
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2022-04-14
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International (CC BY 4.0)
|
DOI |
10.14288/1.0412851
|
URI | |
Affiliation | |
Citation |
Journal of Experimental & Clinical Cancer Research. 2022 Mar 22;41(1):105
|
Publisher DOI |
10.1186/s13046-022-02293-6
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty; Researcher
|
Copyright Holder |
The Author(s)
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International (CC BY 4.0)